United StatesHealth

Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it has entered into an exclusive global license agreement with Pfizer (NYSE:PFE) for ervogastat (formerly PF-06865571), an oral diacylglycerol acyltransferase 2 (DGAT-2) inhibitor currently in Phase 2 development, as well as rights to two additional early-stage metabolic dysfunction-associated steatohepatitis (MASH) assets.

Boston-based Rhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, announced preliminary, unaudited net product revenues for its flagship therapy IMCIVREE (setmelanotide) for the fourth quarter and full year ended December 31, 2025.

Delcath Systems (NASDAQ:DCTH), an interventional oncology company specializing in treatments for primary and metastatic liver cancers, announced preliminary unaudited financial results and business updates for the fourth quarter and full year ended December 31, 2025.

Cartesian Therapeutics (NASDAQ:RNAC) provided an update on its Descartes-08 program, a first-in-class autologous mRNA-engineered CAR-T cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases, and outlined key 2026 priorities.

Schrödinger (NASDAQ:SGDR) announced a strategic collaboration with Eli Lilly and Company (NYSE:LLY) on Friday to integrate Lilly’s high-powered TuneLab™ AI platform directly into Schrödinger’s flagship enterprise software, LiveDesign.

Palvella Therapeutics (NASDAQ:PVLA) issued a comprehensive 2026 corporate update detailing significant progress across its late-stage QTORIN platform, which leverages a proprietary topical rapamycin formulation for the treatment of rare dermatological and vascular conditions.

Aquestive Therapeutics (NASDAQ:AQST) reported that the U.S. Food and Drug Administration has identified deficiencies in the new drug application for Anaphylm (dibutepinephrine), an oral sublingual film formulation for the emergency treatment of Type I allergic reactions, including anaphylaxis.

Perspective Therapeutics (NYSE:CATX) reported updated interim safety and efficacy data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET, a targeted alpha-particle radiopharmaceutical for the treatment of neuroendocrine tumors, with a data cut-off of December 10, 2025.

Amarin Corporation (NASDAQ:AMRN) commented on recent therapeutic advances for patients with elevated triglycerides, asserting that its flagship VASCEPA/VAZKEPA (icosapent ethyl) franchise remains strongly positioned to benefit from broader category commercialization efforts.

California-based MapLight Therapeutics (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on novel therapies for neuropsychiatric disorders, provided an update on the progress of its two ongoing Phase 2 studies.

Liquidia Corporation (NASDAQ:LQDA) reported preliminary, unaudited commercial performance metrics for its lead product YUTREPIA (treprostinil) inhalation powder for the fourth quarter and full year ended December 31, 2025.

Haemonetics Corp. (NYSE:HAE) announced Friday it has acquired Vivasure Medical Limited, a Galway-based pioneer in vessel closure technology, in a move that significantly broadens its reach into the $2.5 billion global vascular closure market.